The contribution of nitric oxide to cardiovascular status and responses to vasodilators in conscious, hypertensive, transgenic ((mRen-2)27) rats

British Journal of Pharmacology

Volumn 124, Issue 2, 1998, Pages 299-306

  Gardiner, S M ^a   March, J E ^a   Kemp, P A ^a   Bennett, T ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Nitric oxide; Transgenic rats; Vasodilator responses

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; BETA 2 ADRENERGIC RECEPTOR; BRADYKININ; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; SALBUTAMOL; VASODILATOR AGENT; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; ENZYME INHIBITION; HEMODYNAMICS; HYPERTENSION; KIDNEY BLOOD VESSEL; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION;

ACETYLCHOLINE; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYKININ; FEMALE; HINDLIMB; HYPERTENSION; KIDNEY; MALE; MESENTERIC ARTERIES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; VASODILATION; VASODILATOR AGENTS;

EID: 0031808370     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701838     Document Type: Article

References (61)

1. ARNAL, J.F., AL AMRANI, A-I., CHATELLIER, G , MÉNARD, J & MICHEL, J-B. (1993). Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension, 22, 380-387.
2. BENNETT, M.A., HILLIER, C. & THURSTON, H. (1996). Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. J. Hypertens., 14, 389-397.
3. BÖHM, M., MOLL, M., SCHMID, B., PAUL, M., GANTEN, D., CASTELLANO. M. & ERDMANN, E. (1994). β-Adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats. Hypertension. 24, 653-662.
4. G-nitro L-arginine methylester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ. Res., 72, 387- 395.
5. CARDILLO, C., KILCOYNE, C.M., QUYYUMI, A.A., CANNON, R.O. & PANZA, J.A. (1997). Decreased vasodilator response to isoproterenol during nitric oxide inhibition in humans. Hypertension, 30, 918-921.
6. DELPY, E. COSTE, H & LE MONNIER DE GOUVILLE, A-C. (1996). Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br. J. Pharmacol., 119, 471-478.
7. DUNN, W.R. & GARDINER, S.M. (1995a). Structural and functional properties of isolated, pressurized, mesenteric resistance arteries from a vasopressin-deficient rat model of genetic hypertension. Hypertension, 26, 390-396.
8. G-nitro-L-arginine methyl ester: methodological considerations for studies of small arteries in hypertension reply. J. Hypertens., 13, 1217-1221.
9. DUNN, W.R. & GARDINER, S.M. (1997). Differential alteration in vascular structure of resistance arteries isolated from the cerebral and mesenteric vascular beds of transgenic [(mRen-2)27], hypertensive rats. Hypertension, 29, 1140-1147.
10. FÉLÉTOU, M. & VANHOUTTE, P.M. (1996). Endothelium-derived hyperpolarizing factor, Clin. Exp. Pharmacol. Physiol., 23, 1082-1090.
11. FERRO, C.J. & WEBB, D.J. (1997). Endothelial dysfunction and hypertension. Drugs, 53, (Suppl. 1), 30-41.
12. FLAIM, S.F. & MINTEER, W.J. (1980). Ventricular volume overload alters cardiac output distribution in rats during exercise. J. Appl. Physiol., 49, 482-490.
13. G-monomethyl-L-arginine in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Br. J. Pharmacol., 102, 823-826.
14. GARDINER, S.M., COMPTON, A.M., BENNETT, T., PALMER, R.M.J. & MONCADA, S. (1990a). Control of regional blood flow by endothelium-derived nitric oxide. Hypertension, 15, 486-492.
15. G-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br. J. Pharmacol., 101, 625-631.
16. G-nitro-L-arginine methyl ester. Br. J. Pharmacol., 101, 632-639.
17. G-nitro-L-arginine methyl ester in conscious, unrestrained rats. J. Cardiovasc. Pharmacol., 17 (Suppl. 3), S173-S181.
18. G-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, 5′-N-ethylcarboxamidoadenosine or salbutamol in conscious rats. Br. J. Pharmacol., 103, 1725-1732.
19. GARDINER, S.M., KEMP. P.A. & BENNETT. T. (1993a). Effects of chronic treatment with nitric oxide synthase inhibitors on regional haemodynamic responses to vasodilators in conscious Brattleboro rats. Br. J. Pharmacol., 109, 222-228.
20. 2-adrenoceptors in the regional haemodynamic responses to bradykinin in conscious rats. Br. J. Pharmacol., 105, 839-848.
21. G,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br. J. Pharmacol., 110, 1457-1464.
22. GARDINER, S.M., MARCH, I.E., KEMP. P.A. & BENNETT, T. (1994). Resting cardiovascular status and vasodilator function in a vasopressin-deficient, hypertensive strain of rat, J. Hypertens., 12, 1217-1224.
23. GARDINER, S.M., MARCH, J.E., KEMP, P.A., MULLINS, J.J. & BENNETT, T. (1995). Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br. J. Pharmacol., 116, 2237-2244.
24. GIL-LONGO, J., FDEZ-GRANDAL, D., ALVAREZ, M., SIEIRA, M. & ORALLO, F. (1996). Study of in vivo and in vitro resting vasodilator nitric oxide tone in normotensive and genetically hypertensive rats. Eur. J. Pharmacol., 310, 175-183.
25. HUANG, A. & KOLLER, A. (1996). Both nitric oxide and prostaglandin-mediated responses are impaired in skeletal muscle arterioles of hypertensive rats. J. Hypertens., 14, 887-895.
26. JOHNSTONE, M.T., CREAGER, S.J., SCALES, K.M., CUSCO, J.A., LEE, B.K. & CREAGER, M.A. (1993). Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 88, 2510-2516.
27. KOLLER, A. & HUANG, A. (1994). Impaired nitric oxide mediated flow-induced dilation in arterioles of spontaneously hypertensive rats. Circ. Res., 74, 416-421.
28. LEE, M.A., BÖHM, M., PAUL, M., BADER, M., GANTEN, U. & GANTEN, D. (1996). Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am. J. Physiol., 270, E919- E929.
29. LI, P., FERRARIO, C.M., GANTEN, D. & BROSNIHAN, K.B. (1997). Chronic estrogen treatment in female transgenic (mRen2)27 hypertensive rats augments endothelium-derived nitric oxide release. Am. J. Hypertens., 10, 662-670.
30. LOUIS, W.J. & HOWES, E.G. (1990). Genealogy of the spontaneously hypertensive rat and Wistar-Kyoto rat strains: implications for studies of inherited hypertension. J. Cardiovasc. Pharmacol., 16 (Suppl. 7). S1-S5.
31. MARCH, J.E., GARDINER, S.M., KEMP, P.A. & BENNETT, T. (1996). Regional haemodynamic responses to vasodilators in conscious, transgenic [(mREN-2)27] hypertensive rats. Br. J. Pharmacol., 117, 227P.
32. G-nitro-L-arginine methyl ester (L-NAME) in conscious, hypertensive transgenic [(mRen-2)27] rats. Br. J. Pharmacol., 122, 116P.
33. MATROUGUI, K., MACLOUF, J., LEVY, B.I. & HENRION, D (1997). Impaired nitric oxide- and prostaglandin-mediated responses to flow in resistance arteries of hypertensive rats. Hypertension, 30, 942-947.
34. MOMBOULI, J-V. & VANHOUTTE, P.M. (1997). Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends Pharmacol. Sci., 18, 252-256.
35. MONCADA, S., REES. D.D. SCHULZ, R. & PALMER. R.M.J. (1991). Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl. Acad. Sci. U.S.A., 88, 2166-2170.
36. MORIGUCHI, A., BROSNIHAN, K. B. KUMACAI, H., GANTEN. D. & FERRARIO. C.M. (1994). Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am. J. Physiol., 266, R1273-R1279.
37. MULLINS, J.J., PETERS, J. & GANTEN, D. (1990). Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature, 344, 541-544.
38. MULVANY. M.J. (1993). Resistance vessel structure and the pathogenesis of hypertension. J. Hypertens., 11 (Suppl. 5). S7-S12.
39. MULVANY, M.J. & KORSGAARD. N. (1983). Correlations and otherwise between blood pressure, cardiac mass and resistance vessel characteristics in hypertensive, normotensive and hypertensive, normotensive hybrid rats. J. Hypertens., 1, 235-244.
40. NOLL, G., LANG, M.G., TSCHUDI, M.R., GANTEN, D. & LÜSCHER, T.F. (1997). Endothelial vasoconstrictor prostanoids modulate contractions to acetylcholine and ANG II in Ren-2 rats. Am. J. Physiol., 272, H493-H500.
41. PEIRO. C., ROSA DE SAGARRA, M., REDONDO, J., SANCHEZFERRER, C.F. & MARÍN, J. (1992). Vascular smooth muscle proliferation in hypertensive transgenic rats. J. Cardiovasc. Pharmacol., 20 (Suppl. 12), S128-S131.
42. PHILLIPS, K., GARDINER, S.M., KEMP, P.A. & BENNETT, T. (1991). Factors affecting the regional haemodynamic responses to glyceryl trinitrate and molsidomine in conscious rats. Br. J. Pharmacol., 104, 151-158.
43. PINTO, Y.M., BUIKEMA, H., VAN GILST. W.H., SCHOLTENS, E., VAN GEEL, P-P., DE GRAEFF, P.A., WAGNER. J. & PAUL, M. (1997). Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J. Mol. Med., 75, 371-377.
44. RODRIGO, E., MAESO, R., MUǸOZ-GARCIA, R., NAVARRO-CID, J., RUILOPE, L.M., CACHOFEIRO, V. & LAHERA, V. (1997). Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J. Hypertens., 15, 613-618.
45. SAWADA. Y., SAKAMAKI, T., NAKAMURA, T., SATO, K., ONO, Z. & MURATA, K. (1994). Release of nitric oxide in response to acetylcholine is unaltered in spontaneously hypertensive rats. J. Hypertens., 12, 745-750.
46. G-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension. J. Hypertens., 13, 817-821.
47. SCHIFFRIN, E.L. (1996). The endothelium of resistance arteries: physiology and role in hypertension. Prost. Leuk. Essent. Fatty Acids, 54, 17-25.
48. SHORE, A.C. & TOOKE, J.E. (1994). Microvascular function in human essential hypertension. J. Hypertens., 12, 717-728.
49. STRAWN, W.B., GALLAGHER, P., DEAN, R. H., GANTEN. D. & FERRARIO, C.M. (1997). Endothelial injury in transgenic (m Ren-2)27 hypertensive rats. Am. J. Hypertens., 10, 51-57.
50. STRUIJKER-BOUDIER, H.A.J., VAN ESSEN, H., FAZZI, G., DE MEY. J.G.R., QIU, H.Y. & LEVY, B.I. (1996). Disproportional arterial hypertrophy in hypertensive mRen-2 transgenic rats. Hypertension. 28, 779-784.
51. THYBO, N.K., KORSGAARD, N. & MULVANY, M.J. (1992). Morphology and function of mesenteric resistance arteries in transgenic rats with low-renin hypertension. J. Hypertens, 10, 1191-1196.
52. TSCHUDI, M.R., NOLL. G., ARNET, U., NOVOSEL, D., GANTEN, D. & LÜSCHER, T.F. (1994). Alterations in coronary artery vascular reactivity of hypertensive Ren-2 transgenic rats. Circulation, 89, 2780-2786.
53. VANHOUTTE, P.M. (1996). Endothelial dysfunction in hypertension. J. Hypertens., 14, (Suppl. 5), S83-S93.
54. WALLER, J., GARDINER, S.M. & BENNETT, T. (1994). Regional haemodynamic responses to acetylcholine, methoxamine, salbutamol and bradykinin during lipopolysaccharide infusion in conscious rats. Br. J. Pharmacol., 112, 1057-1064.
55. G-nitro-L-arginine methyl ester in vitro and in vivo. J. Pharmacol. Exp. Ther., 267, 1091-1099.
56. WANG, Y-X., POON, K.S., RANDALL, D.J. & PANG, C.C.Y (1993). Endothelium-derived nitric oxide partially mediates salbutamol-induced vasodilatations. Eur. J. Pharmacol., 250, 335-340.
57. WHITE, R.M., RIVERA, C.O. & DAVISON, C.B. (1996). Differential contribution of endothelial function to vascular reactivity in conduit and resistance arteries from deoxycorticosterone-salt hypertensive rats. Hypertension, 27, 1245-1253.
58. G-nitro-L-arginine methyl ester in conscious. Long Evans rats. Br. J. Pharmacol., 105, 653-656.
59. WIRTH, K.J. LINZ, W., WIEMER, G. & SCHOLKENS. B.A. (1996). Differences in acetylcholine and bradykinin induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages. Naunyn-Schmiedeberg's Arch. Pharmacol., 354, 38-43.
60. WU, X., MÄKYNEN, M., ARVOLA, P. & PÖRSTI, I. (1996). Mesenteric arterial function in vitro in three models of experimental hypertension. J. Hypertens., 14, 365-372.
61. ZANCHI, A., AUBERT, J.F., BRUNNER, H.R. & WAEBER, B (1995). Vascular acetylcholine response during chronic NO synthase inhibition: in vivo versus in vitro. Cardiovasc Res., 30, 122-129.